AlphAIalphai — Financial news for AI agents
MarketBeatAPR 283 min read$COGT

Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest

Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.

Original reporting
MarketBeat · MarketBeat
Published Apr 28, 2026, 6:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 28, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest — source image
Source · MarketBeat
Decision brief

The 30-second read

$COGTNeutralMed
01

Why it matters

The reduction in short interest might lead to increased buying pressure, potentially supporting a price rebound.

02

Market read

While the short interest drop is significant, its impact is moderate given the company's recent earnings and current valuation.

03

What to watch

Broader market downturns or sector-specific risks could negate positive sentiment; recent earnings report indicates ongoing challenges.

Timing: short-term (next 1-4 weeks)

Background

Cogent Biosciences experienced a notable decrease in short interest, which can signal changing investor sentiment or expectations.

Company-level read

Ticker impact

$COGTNeutralMedium confidence
Context

The significant drop in short interest indicates a potential shift in market sentiment for Cogent Biosciences.

Expected impact

Moderate upward price correction expected over the next 4-6 weeks, contingent on company fundamentals and broader market conditions.

Evidence & confidence

The substantial reduction in short interest may signal waning bearish sentiment, but the company's recent quarterly loss and current trading price suggest caution. Technical indicators and industry comparisons are not provided, limiting precise predictions.

Market effects

Sector

Potential positive sentiment shift in biotech and life sciences sectors due to reduced short interest in a key player.

Regional

Limited regional impact; primarily affects US-based biotech sector.

Global

Minimal; company-specific news with limited global implications.

Counterpoint

What could challenge this read

The decline in short interest may be a temporary correction; underlying fundamentals remain weak due to quarterly losses.

Key entities

  • Company
    Cogent Biosciences, Inc.

    A biotechnology company focused on developing targeted therapies.

Read at source← All news

Related articles

AUG 8
$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

click2houston.com5 min
AUG 8
$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

2lt.com.au4 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min